Navigation Links
New device finds early signs of eye disease in preemies
Date:9/21/2009

DURHAM, N.C. -- Tell-tale signs of a condition that can blind premature babies are being seen for the first time using a new handheld device in a study at Duke University Medical Center.

The technology, developed in part by Duke biomedical engineers, uses spectral domain optical coherence tomography (SD OCT) to create a 3-D picture of the back of the eye. "This new tool is changing the way we identify eye conditions in infants," says Cynthia Toth, MD, an ophthalmologist at the Duke Eye Center, who is leading the study that appears online this month in the journal Ophthalmology.

Retinopathy of prematurity (ROP) is one of the most common causes of vision loss in children, affecting about 16,000 babies each year, according to the National Eye Institute. It occurs when babies are born prematurely and their retinal blood vessels don't develop fully. Instead, the vessels grow abnormally and are prone to leaking and contracting. That can pull the retina out of position, causing retinal detachments that can lead to visual loss and blindness.

Current screening for ROP is based on two-dimensional images taken either with an ophthalmoscope or a camera placed directly on the infant's cornea. "Examining the retina with these methods is like looking at the surface of the ocean and only seeing dimly into the shallow water," says Toth, a professor of ophthalmology and biomedical engineering. "You cannot see what lies below."

SD OCT, on the other hand, uses a narrow beam of light to create a 3-D high-resolution map of the intricate detail in the retina's layers. "This is like looking into an aquarium from the side, where all the fish at every depth are visible," Toth says.

Ophthalmologists at Duke Eye Center pioneered and have been using OCT to accurately diagnose adult eyes for more than a decade, and in the past two years, Toth has been studying the application of this technology for retinal diseases in children.

"SD OCT reveals the retina in greater detail than was ever before realized, allowing us to observe disease at almost the cellular level" she says.

New advances in OCT led Joseph Izatt, a professor of biomedical engineering and ophthalmology at Duke, to create the handheld probe which can snap pictures over 40 times faster than previous versions of OCT. That means multiple scans of the eye now take only seconds. It also means the portable handheld SD OCT system can be taken directly to premature infants in the incubator.

The device is manufactured by Bioptigen, Inc., a Duke spinout company in Research Triangle Park. Izatt is the chairman and chief technology officer of the firm.

"Now, for the first time, we can take the SD OCT system into the neonatal intensive care unit and hold it over the infant's eye without touching the eye and image the retina while the infant is lying in the bed," she says. "We don't have to transport the infants out of the intensive care unit, which makes the whole process much more comfortable for them and their parents."

Toth's next step is to determine what role the system could play in treatment decisions.

"Right now we're analyzing data on more than 20 infants to identify how the SC OCT images of RoP relate to the usual examination and to decisions we make about treatment. What we hope to learn is whether what we see in the infant's eyes today will help us to predict how their disease and vision will be in the future."

Toth says this imaging technology could also have practical applications for improving the diagnosis and treatment of babies suspected of having a wide range of retinal diseases including albinism and retinal injury.


'/>"/>

Contact: Debbe Geiger
Debbe.Geiger@duke.edu
919-660-9461
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. MSU engineering team designs innovative medical device
2. New AnyTrack GPS Devices Track Assets Indoors, Outdoors or Hidden
3. Implantable device designed to detect, stop seizures under study at MCG
4. Visiprise Launches Podcast Series with AMR to Support Medical Device Manufacturers
5. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
6. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
7. New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours
8. Mobility-enhancing device developed at University of Alberta will receive prestigious da Vinci Award
9. Design Resource Extends Support for Orthopaedic and Cardiovascular Devices
10. FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use
11. FDA approves knee-injury device for humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Yardley, PA (PRWEB) , ... March 23, 2017 ... ... received Patient Oriented Disease Management Accreditation from the NCQA. The accreditation covers StayWell’s ... programs. , Accredited status is granted to organizations that have excellent programs ...
(Date:3/23/2017)... ... , ... The TouchPoint Solution, home of Buzzies *, is boosting the ... , “Buzzies change the way we interact with stress and live our day-to-day lives,” ... date in December 2016, The TouchPoint Solution has sold more than $750,000 in product ...
(Date:3/23/2017)... , ... March 23, 2017 , ... After raising more ... FaceCradle , the most-funded travel pillow in crowdfunding history, has established a ... its wildly popular travel innovation to Americans. , “We’re excited to be operating on ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... today announced rapid completion of the strategic executive team expansion needed to further ... to the ChenMed executive team,” says Christopher Chen, MD, ChenMed Chief Executive Officer. ...
(Date:3/23/2017)... ... March 23, 2017 , ... Natural Subsistence, ... aspects of people’s health and nutrition, announced its product Leyzene is now available ... Subsistence develops nutritional supplements that help people improve all aspects of their health ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... MUMBAI , March 23, 2017 ... de Piramal Enterprises Limited, anuncia el nombramiento de ... PPS ofrece una plataforma de servicios integrados completa ... Needleman desempeñará un cargo clave en el crecimiento ... comercial, Needleman será responsable de impulsar todas las ...
(Date:3/23/2017)... 23, 2017  Galmed Pharmaceuticals Ltd. (Nasdaq: ... clinical-stage biopharmaceutical company focused on the development of ... nonalcoholic steatohepatitis, or NASH, and other liver diseases, ... twelve months ended December 31, 2016, and announced new ... demonstrating Aramchol™,s potential direct effect on liver fibrosis. ...
(Date:3/23/2017)... 23, 2017 ReNeuron reported in December ... in chronic stroke patients, despite not meeting the three-month time ... the Action Research Arm Test (ARAT). As a result, the ... controlled clinical study in 2017. Beyond CTX, we expect safety ... 2017 and Phase I data from its critical limb ischaemia ...
Breaking Medicine Technology: